

Index

- aak-1, 4
 Aβ deposition, 45
 Abbreviated Mental Test Score (AMTS), 17
 abnormal beliefs, assessment, 19
 abnormal perceptions, assessment, 19–20
 absorption, 178
 abuse, elder, 277–9
 accelerated biological ageing, 153
 ACE. *See* Addenbrooke's cognitive examination
 acetylcholine (ACh), 179
 acetylcholinesterase inhibitors (AChEIs), 179
 ACh. *See* acetylcholine
 AChEIs. *See*
 acetylcholinesterase inhibitors
 activities of daily living (ADL), history and, 18
 acute grief, 115
 AD. *See* Alzheimer's disease
 Addenbrooke's cognitive examination (ACE), 38, 70–1, 291
 ADHD. *See* attention deficit hyperactivity disorder
 ADHD Self-Report Scale (ASRS), 166
 adherence, 185
 ADL. *See* activities of daily living
 advance care planning, 240–1
 advanced glycation end products (AGEs), 6
 adverse drug reaction, 299–300
 age-blind services, 270
 AGECA, 24–6
 ageing
 accelerated biological, 153
 cognitive, 6
 complexity of, 1
 immune system, 6
 memory and, 27
 mental illness and, 6–8
 physical, 6
 physiological, 6
 ageing theories, 1
 calorie restriction and, 5–6
 disposable soma theory, 5
 genetics in, 4
 longevity genes in, 4
 sugar and, 6
 Age-Related White Matter Changes (ARWMC), 83
 AGEs. *See* advanced glycation end products
 aggression, ECT for, 196
 agnosia, in AD, 69
 agoraphobia, 146
 agrammatism, 104–5
 AIREN. *See* Association Internationale pour la Recherche et l'Enseignement en Neurosciences
 alcohol consumption, 295–6
 brain damage and, 159–63
 delirium and, 59
 delirium tremens, 158
 dependence, 157–8
 epidemiology of, 153–4
 history of, 18, 156
 lifestyle choices, 9–10
 medical disorders, 160
 psychiatric disorders and, 157
 psychosis and, 136–7
 risk and, 154
 screening, 156–7
 withdrawal, 160
 alcohol related dementia (ARD), 159–63
 Alzheimer, Alois, 68
 Alzheimer's disease (AD), 1–2, 30, 41–2, 113–14, 292–3
 aetiology, 73–4
 agnosia in, 69
 amnesia in, 68–9
 amyloid hypothesis, 74
 aphasia in, 69
 attentional disorders in, 28
 biological management of, 75
 biomarkers, 45
 brain imaging in, 72
 caregivers, 76
 cholinergic hypothesis, 74
 clinical features of, 68
 clinical findings in, 72
 cognitive testing, 70–1
 diagnostic classification, 72–3
 differential diagnosis, 73
 in DSM-5, 72
 EEG in, 71–2
 epidemiology, 67
 FDG-PEG in, 46
 gender and, 68
 history of, 68
 in ICD-10, 72–3
 incidence, 67–8
 investigations, 71
 lifestyle choices and, 75
 memory in, 75–6
 mental state examination in, 70
 pharmacodynamics in, 179
 physical examination in, 71
 physiology, 179
 prevalence, 67–8
 principles of management, 75–6
 prognosis, 76–7
 psychological management of, 75
 psychosis in, 133
 risk factors, 73–4
 social activity in, 76
 tau hypothesis, 74
 treatment strategies, 179
 VaD and, 82
 ambivalence, 10
 AMHP. *See* Approved Mental Health Professional
 amisulpride, 139–40
 amnesia
 in AD, 68–9
 clinical features of, 68–9
 amnesic syndromes, 159–63
 AMTS. *See* Abbreviated Mental Test Score
 amyloid hypothesis, AD, 74
 amyloid PET, 72

- amyloid precursor protein (APP), 73–4
 amyloid scans, 45–6
 anterograde memory, 32
 antidepressants, 119, 182–3
 for Lewy body dementia, 95
 tricyclic, 148–9
 antioxidants, 5
 antipsychotic agents
 delirium and, 61–2
 for Lewy body dementia, 96
 anxiety disorders. *See also*
 generalised anxiety disorder
 assessment of, 147–8
 benzodiazepines for, 149
 CBT and, 213
 classification of, 144
 differential diagnosis, 144, 299
 epidemiology, 143–4
 exam tips, 299
 measures of, 148
 non-pharmacological treatment, 149
 in older adults, 144–5
 pharmacological treatment, 148
 phenomenology, 144
 prevalence of, 143–4, 150
 risk assessment, 299
 social, 146
 SSRIs for, 148–9
 substance misuse and, 154
 subthreshold, 147
 aphasia, 293–4. *See also*
 primary progressive aphasia
 in AD, 69
 progressive programmatic, 105
 apolipoprotein E4 (APOE4), 11, 59, 89
 APP. *See* amyloid precursor protein
 appearance, assessment, 19
 apperceptive agnosias, 29
 Approved Mental Health Professional (AMHP), 270
 apraxia of speech, 35–6, 104–5
 progressive, 105
 APS. *See* atypical parkinsonian syndromes
 Arctic Circle, 223
 ARD. *See* alcohol related dementia
 aripiprazole, 128–9
 arterial spin labelling (ASL), 45
 ARWMC. *See* Age-Related White Matter Changes
 asenapine, 128–9
 ASL. *See* arterial spin labelling
 ASRS. *See* ADHD Self-Report Scale
 Association Internationale pour la Recherche et l'Enseignement en Neurosciences (AIRESN), 80
 asylum seekers
 age cut-offs, 283–4
 defining, 282
 needs of, 286–7
 scale of problems with, 282–3
 ATLAS Study, 139–40
 Atomoxetine, 172
 attention, 27
 span, 28
 attention deficit hyperactivity disorder (ADHD), 165, 174
 adverse effects of medication, 172
 assessment, 165–6, 169
 baseline tests, 171
 comorbid conditions, 168–9
 co-prescribing, 173
 diagnosis, 165–6
 differential diagnosis, 167–8
 impairment of function in, 167
 length of treatment, 169
 medication choice, 171–2
 medication effects, 169–71
 models, 174
 monitoring, 172
 in older age, 172–3
 prevalence of, 166–7
 in prison populations, 173
 service provisions, 173–4
 treatment guidelines, 169
 treatment initiation, 171
 validity of, 166–7
 attentional disorders, in Alzheimer's disease, 28
 attenuated delirium syndrome, 56
 atypical parkinsonian syndromes (APS), 48
 autonomic dysfunction
 in Lewy body dementia, 91
 management of, 96
 autonomy, 269
 care homes and, 250–1
 baby boomers, 220–1
 BADLS. *See* Bristol Activities of Daily Living Scale
 BADS. *See* Brief Anxiety and Depression Scale
 basal ganglia, 32–3
 BASDEC. *See* Brief Assessment Schedule Depression Cards
 BDNF. *See* brain-derived neurotrophic factor
 BDRS. *See* Blessed Dementia Rating Scale
 behavioral and psychological symptoms of dementia (BPSD), 69–70, 240
 care homes and, 252–3
 causes of, 70
 pharmacological management of, 181–2
 behaviour, assessment, 19
 beneficence, 269–70
 benzodiazepines, 18, 154–5
 for anxiety disorders, 149
 delirium and, 62
 withdrawal, 158
 Besson, John, 41
 beta-carotene, 5
 biological management, of AD, 75
 biomarkers, in OABD, 125–6
 biopsychosocial model, 234
 bipolar disorder, 6–7. *See also*
 older-age bipolar disorder
 ECT for, 193
 medications for, 184
 Blessed Dementia Rating Scale (BDRS), 24–6
 blood sugar, 3–4
 body mass index (BMI), 3–4
 BPSD. *See* behavioral and psychological symptoms of dementia
 brain imaging, 72, 82–4
 brain-derived neurotrophic factor (BDNF), 125
 breathing difficulties, 244
 Brief Anxiety and Depression Scale (BADS), 148
 Brief Assessment Schedule Depression Cards (BASDEC), 23–4

- Bristol Activities of Daily Living Scale (BADLS), 24
- British Refugee Council, 284
- Broca's aphasia, 30–1, 35–6
- C9orf72, 49
in FTD, 107
- CADASIL, 46–7
- CAGE questionnaire, 156–7
- CAM. *See* confusion
assessment method
- Cambridge Examination for Mental Disorders of the Elderly (CAMDEX), 23–6
- CAMCOG, 23
- CAMDEX. *See* Cambridge Examination for Mental Disorders of the Elderly
- Canadian Consortium on Neurodegeneration, 51
- cancer, mental illness and, 7
- CanMEDS framework, 217
- capacity, 269
assessment of, 272
for decision making, 262
for research participation, 272–3
testamentary, 275–6
- CAPE. *See* Clifton Assessment Procedures for the Elderly
- Capgras syndrome, 92
- cardiac complications, in ECT, 197
- CARE. *See* Comprehensive Assessment and Referral Evaluation
- care approaches, in OABD, 128
- care homes
autonomy and, 250–1
BPSD and, 252–3
decision making and, 250–1
dementia and, 255–6
dignity and, 250–1
human rights and, 250–1
Lewy body dementia and, 98
long term care and, 251–2
models, 253–5
polypharmacy in, 256–7
- caregivers
AD, 76
CBT and, 212–13
- carers
caring for, 263–4
coping of, 264
as decision makers, 261
- difficulties of, 264–5
grief and, 245–6
interventions for, 265–6
interviews with, 16
medications and, 186
- catatonia, ECT for, 195–6
- CBT. *See* cognitive behaviour therapy
- Celsus, Aulus Cornelius, 54
- cerebellum, 32–3
- change, lifestyle choices and, 10
- cholinergic hypothesis, AD, 74
- cholinesterase inhibitors, 84
for Lewy body dementia, 95
- chronic disease, 1
- circuit Papez, 33
- classic cognitive domains, 27
- Clifton Assessment Procedures for the Elderly (CAPE), 23–6
- clinical assessment, 15
- Clinical Dementia Rating, 38
- Clock Drawing Test, 23
- clonazepam, 96
- CMRglc, 72
- Cochrane Reviews, 243
- cognition
assessment, 20, 28–30
classic cognitive domains, 27
defining, 27–8
ECT and, 196–7
in Lewy body dementia, 90–1
neural basis, 28
in OABD, 127–8
pathologies, 28
psychological models of, 28
- cognitive ageing, 6
- cognitive assessment, 27–8
- cognitive behaviour therapy (CBT), 117, 149, 161, 205
anxiety and, 213
caregivers and, 212–13
dementia and, 212–13
depression and, 213
early phase, 211
efficacy of, 211–12
information processing
errors in, 208–9
middle phase, 211
with older people, 208–11
- cognitive impairment, 37, 655.91. *See also* mild cognitive impairment
- depression and, 113–14
- diagnosis in, 292–5
- differential diagnosis, 291, 293–5, 297
- ECT and, 193
- exam tips, 291, 294–5, 297–8
- steps in, 295–6
- cognitive scales, 22–3
- cognitive testing, AD, 70–1
- collaborators, 221–2
- communicators, 220–1
- Comprehensive Assessment and Referral Evaluation (CARE), 24
- comprehensive assessments, 24
- concentration, 27
in MMSE, 23
- confusion assessment method (CAM), 60
- constipation
in Lewy body dementia, 96–8
management of, 96–8
- consultation-liaison history, 230
models, 231–2
principles, 232–4
research on, 234
scope of, 230–1
training, 235
- co-residence, 284
- corticobasal degeneration, 49
- Court of Protection, 275
- CSF biomarkers, in Lewy body dementia, 94
- CT, 42–3
in VaD, 82–3
- cultural competence, psychiatry and, 16
- daf-2, 4
- DAT. *See* dopamine transporter
- death rattle, 244
- decision making
capacity for, 262
care homes and, 250–1
carers and, 261
in end of life care, 241–2
for family, 262–7
proxy, 272
- default mode network (DMN), 33
- delirium, 27–8, 36–8
aetiology of, 57–9
alcohol consumption and, 59
antipsychotic agents and, 61–2

- delirium (cont.)
 assessment, 60–1
 attenuated, 56
 benzodiazepines and, 62
 classification, 55–6
 clinical features, 59–60
 comorbidity, 56
 core features of, 36
 defining, 55–6
 diagnosis, 60–1
 epidemiology of, 56–7
 future research on, 62
 haloperidol in, 61–2
 history of, 54–5
 in hospitalization, 57
 hyperactive, 59
 hypoactive, 59
 incidence of, 56–7
 inflammatory cytokines and, 59
 management, 61
 medications for, 183
 neuroinflammation and, 59
 in palliative care, 58–9
 polypharmacy and, 61
 presentation of, 59
 prevalence of, 56–7
 prevention of, 62
 prognosis, 61–2
 psychosis and, 135
 risk factors for, 57–8
 subsyndromal, 56
 synonyms, 55
 treatment, 138–9
- delirium tremens, 158
- delusional disorder
 psychosis and, 135–6
 treatment, 135–40
- delusions, in Lewy body dementia, 92
- dementia, 1–2, 27–8, 36–8, 535.120. *See also*
 frontotemporal dementia;
 Lewy body dementia;
 vascular dementia
- care homes and, 255–6
 CBT and, 212–13
 clinical criteria for, 37
 comorbidity, 56
 core features of, 36
 depression and, 113–14, 119
 in end of life care, 257
 environment design for, 255–6
 FDG-PEG in, 46
 in PD, 49
- prevalence of, 216
 progression towards, 46
 psychosis and, 133–5
 rare, 49
 selected, 37–8
 sleep and, 265
 subcortical ischaemic vascular, 80
 treatment, 137–8
- demoralisation, 115–16
- depression, 27–8, 96.10. *See also* major depressive disorder
 CBT and, 213
 cognitive impairment and, 113–14
 core features of, 36
 dementia and, 113–14, 119
 ECT for, 192–3
 imaging in, 49–51
 medications for, 183–4
 in OABD, 129
 physical factors, 114
 prevalence of, 38, 216
 psychosis and, 200
 rTMS for, 199
 scales, 23–4
 treatment, 117, 129, 223–4
- Depressive Signs Scale, 24
- deprivation of liberty
 safeguards (DoLS), 273–5
- Dexamphetamine, 171–2
- DFN. *See* default mode network
- diabetes, mental illness and, 7
- Diagnostic and Statistical Manual of Mental Disorders* (DSM-5), 21–2, 55–6, 123–4, 144–50
 AD in, 72
- diagnostic systems, 21–2
- diffusion tensor imaging (DTI), 41–9
- dignity, care homes and, 250–1
- disability, risk factors for, 2–3
- disconnection syndrome, 47
- disposable soma theory, 5
- distribution, 178
- DLB. *See* Lewy body dementia
- doctors, defining, 225
- DoLS. *See* deprivation of liberty safeguards
- domiciliary visits, 16
- donepezil
 pharmacokinetics of, 179–80
 tolerability of, 179–80
- dopamine, 59
- dopamine transporter (DAT), 48, 90
- Driver and Vehicle Licensing Authority (DVLA), 276–7
- driving, 276–7
- drug interactions, 154–5
- DSM-5. *See* Diagnostic and Statistical Manual of Mental Disorders
- DTI. *See* diffusion tensor imaging
- Dunedin Multidisciplinary Health and Development Study, 11
- DVLA. *See* Driver and Vehicle Licensing Authority
- dysfunction, evidence of, 15–16
- E. Coli, 4
- ECT. *See* electroconvulsive therapy
- EEG. *See* electroencephalogram
- elder abuse, 277–9
- elderly people, with mental illness, 7–8
- electroconvulsive therapy (ECT), 190
 age groups and, 192
 for aggression, 196
 for bipolar disorder, 193
 cardiac complications in, 197
 for catatonia, 195–6
 cognition and, 196–7
 cognitive impairment and, 193
 for depression, 192–3
 dose, 198–9
 efficacy of, 191–2
 electrode placement in, 193–4
 maintenance, 194
 for mania, 195
 for MDD, 118–19
 medication in, 199
 mortality, 197–8
 in older adults, 190–1
 for psychosis, 195
 pulse width, 194, 198
 side-effects, 196
 speed of response to, 192
 workup, 198
- electroencephalogram (EEG), 42–3, 58–9
 in AD, 71–2
- end of life care
 decision making in, 241–2
 defining, 239

- dementia in, 257
 uncertainty at, 240
- endocrine system, ageing and, 6
- engagement, 117–18
- England, morbidity in, 2
- Entrustable Professional Activities (EPAs), 217
- epidemiology, of delirium, 56–7
- EQ-5D, 24–5
- Equality Act, 270
- ethics, 269–70
- etorhinal cortex, 72
- EuroQol Group, 24–5
- examination, 38–9
- excretion, 178
- executive function, 27
 assessment of, 34
 defining, 33–4
 neural basis, 34
 pathologies, 34
 psychological models, 33–4
- exercise, lifestyle choices, 8–9
- FA. *See* fractional anisotropy
- family history, in psychiatry, 17
- fatigue, 27
- Fazekas scale, 47
- FDG-PET, 41, 45, 48–9, 72
 in AD, 46
 in dementia, 46
- fear of falling (FOF), 145–6
- fibre, 9
- FLAIR, 41
- FOF. *See* fear of falling
- FP-CIT SPECT, 48
- fractional anisotropy (FA), 45
- FRAMES approach, 161
- Framingham Heart Study, 10–11
- free radicals, 5
- frontal lobes, 34
- frontal tumour, 294
- frontotemporal dementia (FTD), 37, 42, 48–9, 127–8
 aetiology of, 106
 behavioural variant, 102–3
 C9orf72 in, 107
 classification of, 102
 clinical features, 102
 demographics, 101
 diagnosis of, 107
 frequency of, 108
 GRN in, 106–7
 hallucinations in, 102–3
 historical context of, 101
 MAPT and, 106
- MND and, 105
 mutations in, 107
 non-pharmaceutical interventions, 108
 overlap, 106
 Parkinsonism in, 106
 pharmaceutical interventions, 108–9
 prognosis, 109
 psychosis in, 133
- FTD-MND, 38–9
- functional imaging, in Lewy body dementia, 93
- functional MRI, 42–3
- GAD. *See* generalised anxiety disorder
- GAI. *See* Geriatric Anxiety Inventory
- galantamine, 84
- pharmacokinetics of, 180
- GDS. *See* Geriatric Depression Scale
- gender, AD and, 68
- general practitioners (GPs), 252
- generalised anxiety disorder (GAD), 143–4, 298–9
- genetics
 in ageing theories, 4
 Lewy body dementia, 89
 in VaD, 81–2
- genome-wide association studies (GWASs), 125–6
- Geriatric Anxiety Inventory (GAI), 148
- Geriatric Depression Scale (GDS), 23
- Geriatric Mental State (GMS), 24–6
- gnosis, 23
- GPs. *See* general practitioners
- Greiner, Georg, 54
- grief, 244–5
 acute, 115
 carers and, 245–6
- GRN, 49
 in FTD, 106–7
- GWASs. *See* genome-wide association studies
- Hachinski criteria, in VaD, 80
- Hachinski Ischaemia Score, 24–6
- haematology, 21
- Halcyon, 11
- hallucinations, 69–70
 in Lewy body dementia, 90, 95–6
- haloperidol
 in delirium, 61–2
 in schizophrenia, 139
- Hamilton Depression Rating Scale, 113
- Hamilton Rating Scale, 24
- HAS. *See* History and Aetiology Schedule
- Hayflick Limit, 4–5
- Hayling Sentence Completion Test, 34
- HbA1C, 71
- health advocacy, 223–4
- Health in Men Study (HIMS), 124
- health inequalities, 284–6
- Health of the Nation Outcome Scales 65+ (HoNOS 65+), 24
- healthy ageing
 assessment of, 6
 biomarkers, 6
- HIMS. *See* Health in Men Study
- history
 activities of daily living and, 18
 of alcohol consumption, 18, 156
 family, 17
 of medications, 18
 past psychiatric, 17
 in psychiatry, 17
- History and Aetiology Schedule (HAS), 24–6
- history taking, 38–9
- HoNOS 65+. *See* Health of the Nation Outcome Scales 65+
- hospitalization, delirium in, 57
- HPA axis. *See* hypothalamic-pituitary-adrenal axis
- Human Connectome Project, 51
- human rights, care homes and, 250–1
- Huntington's disease, 49
- hydration, in palliative care, 243–4
- hyperactive delirium, 59
- hypertension, 3–4
- hypoactive delirium, 59
- hypothalamic-pituitary-adrenal (HPA) axis, 144

- ICD-10. *See* International Classification of Diseases and Related Health Problems
- idiopathic normal pressure hydrocephalus, 49
- imaging. *See also specific techniques*
 brain, 72, 82–4
 in depression, 49–51
 diffusion tensor, 41–9
 functional, 93
 magnetic resonance, 41, 45, 49, 79–83
 modalities, 42
 molecular, 83
 structural, 92–3
 Whitehall-II Imaging sub-study, 51
- IMCA. *See* Independent Mental Capacity Advocate
- immune system, ageing, 6
- Independent Mental Capacity Advocate (IMCA), 273
- infections, in palliative care, 244
- inflammatory cytokines, delirium and, 59
- information processing, 27
- insomnia, substance misuse and, 154
- insulae, 35
- International Classification of Diseases and Related Health Problems (ICD-10), 21–2, 56
 AD in, 72–3
- interpersonal psychotherapy (IPT), 205–7
- interviews
 with carers, 16
 in psychiatry, 16
 with relatives, 16
- intravenous drug misuse, 160
- investigations, 21
- IPT. *See* interpersonal psychotherapy
- Kirkwood, Tom, 5
- Korsakoff's syndrome, 33, 159–63, 295
- Kraepelin, Emil, 68
- language, 27
 assessment, 31–2
 definitions, 30
 in MMSE, 23
- neural basis for, 30–1
 pathologies, 30–1
 psychological models, 30
- large vessel disease, 46–7
- Lasting Power of Attorney (LPA), 273
- late-onset schizophrenia, 135–6
 treatment, 135–40
- leadership, 222–3
- levodopa, for Lewy body dementia, 96
- Lewy, Frederick, 88
- Lewy body dementia (DLB), 28, 30, 48
 antidepressants for, 95
 antipsychotic agents for, 96
 apathy in, 92
 autonomic dysfunction in, 91
 care homes and, 98
 cholinesterase inhibitors for, 95
 clinical features, 89
 cognition in, 90–1
 constipation in, 96–8
 CSF biomarkers in, 94
 delusions in, 92
 diagnosis of, 48
 functional imaging in, 93
 genetics, 89
 hallucinations in, 90, 95–6
 hyposmia in, 92
 levodopa for, 96
 management of, 95
 MCI in, 94–5
 medications for, 178
 mortality in, 98–9
 neuroleptic sensitivity in, 91–2
 Parkinsonism in, 90
 pathology, 88–9
 prodromal, 94–5
 prognosis, 98
 psychosis in, 133
 psychostimulants for, 95
 QoL in, 98
 RBD in, 91
 structural imaging in, 92–3
 symptoms of, 94
 tracers in, 93
 treatment strategies, 97–8
- life expectancy, 1–2
 health and, 2
- Lifebrain, 51
- lifestyle choices
 AD and, 75
 alcohol consumption, 9–10
- changing, 10
 exercise, 8–9
 mental stimulation, 9
 nutrition, 9
 physical activity, 9
 sexual activity, 8
 sleep, 9
 smoking, 9–10
 social activity, 8
 VaD and, 84
- life-style decisions, 1
- limbic encephalitis, 49
- lithium, 184
- LMNA gene, 4
- long term care, 251–2
- longevity, 1–2
- longevity genes, in ageing theories, 4
- loss, 244–5
- Lothian Birth Cohort Study, 11
- LPA. *See* Lasting Power of Attorney
- MADRS. *See* Montgomery-Asberg Depression Rating Scale
- magnetic resonance imaging (MRI), 41, 45, 49
 in VaD, 79–83
- major depressive disorder (MDD)
 aetiology of, 114–15
 assessment of, 115
 classification of, 112
 differential diagnosis, 115–16
 ECT for, 118–19
 epidemiology of, 112–13
 pharmacotherapy for, 118
 prevention of, 116–17
 prognosis, 120–1
 suicide and, 119–20
- mania, ECT for, 195
- MAOI. *See* monoamine oxidase inhibitors
- MAPT. *See* mutations in tau
- Marshall, Mary, 255
- MCI. *See* mild cognitive impairment
- MDD. *See* major depressive disorder
- medial temporal atrophy (MTA), 42
- medial temporal lobe (MTL), 42
- medical experts, 217–20
- medical history, in psychiatry, 17–18

- medications
 carers and, 186
 in ECT, 199
 history of, 18
 pharmacies and, 186–7
 primary care and, 186
 review of, 185
 teams, 186
 melatonin, 62
 memantine, 84, 182
 indications for, 180–1
 pharmacokinetics of, 180–1
 tolerability of, 180–1
 memory, 27
 in AD, 75–6
 ageing and, 27
 anterograde, 32
 assessment, 33
 defining, 32
 in MMSE, 22–3
 neural basis, 32–3
 pathologies, 32–3
 prospective, 32
 psychological models, 32
 retrograde, 32
 working, 33–4
 Mental Capacity Act, 272–4, 276
 Mental Health Act (MHA), 270–2
 mental illness
 ageing and, 6–8
 cancer and, 7
 diabetes and, 7
 elderly people with, 7–8
 metabolic syndrome and, 7
 mental state, in psychiatry, 19–21
 mental state examination, in AD, 70
 mental stimulation, lifestyle choices, 9
 MET. *See* motivational enhancement therapy
 metabolic syndrome
 mental illness and, 7
 in OABD, 126
 metabolism, 178
 metaiodobenzylguanidine (MIBG), 88
 MHA. *See* Mental Health Act
 MIBG. *See* metaiodobenzylguanidine
 mild cognitive impairment (MCI), 36–8, 46
 in Lewy body dementia, 94–5
 Mini-Mental State Examination (MMSE), 17–22, 221–2, 252
 concentration in, 23
 language in, 23
 memory in, 22–3
 orientation, 22
 MMSE. *See* Mini-Mental State Examination
 MND. *See* motor neurone disease
 MoCA. *See* Montreal cognitive assessment
 molecular imaging, VaD, 83
 monoamine oxidase inhibitors (MAOI), 148–9, 183–4
 Montgomery-Asberg Depression Rating Scale (MADRS), 24
 Montreal cognitive assessment (MoCA), 38, 70–1
 mood, assessment, 19
 mood disorders, 27
 psychosis and, 135
 treatment, 138
 morbidity
 causes of, 2–3
 in England, 2
 risk factors for, 3–4
 Mormon, Deham, 5
 mortality gap, physical health and, 6–8
 motivational enhancement therapy (MET), 161
 motivational interviewing, 10, 161
 motor neurone disease (MND), FTD and, 105
 MRI. *See* magnetic resonance imaging
 MRS, 42–3
 MTA. *See* medial temporal atrophy
 MTL. *See* medial temporal lobe multidisciplinary care, palliative, 239–40
 multiple sclerosis, 49
 multiple system atrophy, 49
 mutations in tau (MAPT), 49, 101
 FTD and, 106
 National Health and Nutrition Study (NHANES), 11
 National Health Survey Trusts, 191–201
 National Institute for Health and Clinical Excellence (NICE), 165
 National Institute for Mental Health, 191–201
 National Institute for Neurological Disorders and Stroke (NINDS), 80
 neglect, 277
 neurodegeneration, 46
 neuro-fibrillary tangles (NFTs), 42
 neuroinflammation, delirium and, 59
 neuroleptic sensitivity, in Lewy body dementia, 91–2
 neuropathology, in OABD, 125–6
 neurosyphilis, 294
 Newcastle 85+ Study, 11
 NFTs. *See* neuro-fibrillary tangles
 NHANES. *See* National Health and Nutrition Study
 NICE. *See* National Institute for Health and Clinical Excellence
 NINDS. *See* National Institute for Neurological Disorders and Stroke
 non-maleficence, 269–70
 Norman, Connolly, 54
 Nu-DESC, 60
 Nun Study, 11
 nutrition
 lifestyle choices, 9
 in palliative care, 243–4
 OABD. *See* older-age bipolar disorder
 oculomotor apraxia, 29
 oestrogen, 6
 olanzapine, 61–2, 139
 older adults
 anxiety disorders in, 144–5
 CBT with, 208–11
 ECT in, 190–1
 PST for, 207
 psychoanalytical approaches and, 206
 psychological therapies with, 206
 RT with, 207–8
 older-age bipolar disorder (OABD), 123
 biomarkers in, 125–6
 care approaches in, 128
 clinical features, 123

- older-age bipolar disorder (OABD) (cont.)
 cognition in, 127–8
 depression in, 129
 diagnosis of, 123–4
 epidemiology, 123
 guidelines, 128–9
 metabolic syndrome in, 126
 neuropathology in, 125–6
 parathyroid dysfunction in, 126
 physical health in, 126
 prevalence of, 124–5
 renal failure in, 126–7
 thyroid dysfunction in, 126
 weight gain in, 126
- Omega 3, 84
 Omega 6, 84
 opioids, 154–5
 optic ataxia, 29
 optimism, 10
 outcome scales, 24
 out-patient departments, 16
- p53, 5
 pain
 identification of, 242
 management of, 242–3
 in palliative care, 242
 scales, 242
 substance misuse and, 154
- palliative care
 breathing difficulties in, 244
 defining, 239
 delirium in, 58–9
 hydration in, 243–4
 infections in, 244
 multidisciplinary, 239–40
 nutrition in, 243–4
 pain in, 242
 symptom control in, 242
- panic disorder, 146–7
 PAOS. *See* progressive apraxia of speech
- parathyroid dysfunction, in OABD, 126
- Parkinsonism
 in FTD, 106
 in Lewy body dementia, 90
- Parkinson's disease (PD), 45–6
 dementia in, 49
 psychosis in, 136
 treatment, 137–8
- Parkinson's disease dementia (PDD), 88
 medications for, 178
- passage hallucinations, 136
 past psychiatric history, 17
 patient rating outcome measures (PROMS), 24–5
 PD. *See* Parkinson's disease
 PDD. *See* Parkinson's disease dementia
- peak physical function, 1
 perceptions, assessment, 19–20
 perceptual skills, 27
 perfusion MRI, 42–3
 persistent complex bereavement disorder, 245
- personal history, in psychiatry, 17
- PET, 42–3, 108.120. *See also* FDG-PET
- pharmacies, medications and, 186–7
 pharmacodynamics, 178–9
 in AD, 179
 pharmacokinetics
 defining, 178
 of donepezil, 179–80
 of galantamine, 180
 of memantine, 180–1
- phobias
 agoraphobia, 146
 fear of falling, 145–6
 social anxiety disorder, 146
 specific, 145
- physical activity, lifestyle choices, 9
 physical ageing, 6
 physical examination, 16
 in AD, 71
 assessment, 21
- physical function
 decline in, 1
 peak, 1
- physical health
 mortality gap and, 6–8
 in OABD, 126
- physiological ageing, 6
 physostigmine, 179
- Pick bodies, 101
 pit-1, 4
 Pitt, Brice, 15–16
 polypharmacy, 185
 in care homes, 256–7
 delirium and, 61
- PPA. *See* primary progressive aphasia
- praxis, 23
 definitions, 35
 neural basis, 35–6
- pathologies, 35–6
 psychological models, 35
- prefrontal cortex, 34
 premorbid personality, 19
 presenilin-1 (PS-1), 73
 presenilin-2 (PS-2), 73
 PRIDE. *See* Prolonging Remission in Depressed Elderly
- primary care, medications and, 186
- primary progressive aphasia (PPA), 35–6, 103
 features, 31
 logopenic variant, 102–3, 105
 non-fluent, 49, 102–5
 semantic variant, 49, 102–4
- principles, 269–70
 prion diseases, 49
 prison populations, ADHD in, 173
- problem-solving therapy (PST), 205, 221
 with older people, 207
- Prodromal Lewy body dementia, 94–5
- professionals, 225–6
 progenia, 4
 progenin, 4
- progressive apraxia of speech (PAOS), 105
- progressive programmatic aphasia, 105
- progressive supranuclear palsy, 49
- Prolonging Remission in Depressed Elderly (PRIDE), 194–5
- PROMS. *See* patient rating outcome measures
- prosopagnosia, 30
 prospective memory, 32
 proteinopathies, 46
 proxy-decision making, 272
- PS-1. *See* presenilin-1
 PS-2. *See* presenilin-2
- PST. *See* problem-solving therapy
- psychiatric disorders
 alcohol consumption and, 157
 substance misuse and, 157
- psychiatrists, role of, 216
- psychiatry, 15
 assessment locations, 15–16
 cultural competence and, 16

- family history in, 17
 history in, 17
 history of medications in, 18
 interviews in, 16
 medical history in, 17–18
 mental state in, 19–21
 personal history in, 17
 setting in, 16–17
 social history in, 18–19
 psychoanalytical approaches,
 older people and, 206
 psychogenesis, 234
 psychological management, of
 AD, 75
 psychological models, of
 cognition, 28
 psychological therapies, 205–6
 with older adults, 206
 psychosis, 294, 298
 in AD, 133
 alcohol consumption and,
 136–7
 common causes of, 133–4
 consequences of, 137
 delirium and, 135
 delusional disorder and,
 135–6
 dementia and, 133–5
 depression and, 200
 differential diagnosis, 298
 drug use and, 136–7
 ECT for, 195
 exam tips, 298
 in FTD, 133
 in Lewy body dementia, 133
 management of, 137
 medications for, 184
 mood disorders and, 135
 in Parkinson's disease, 136
 schizophrenia and, 135–6
 substance misuse and, 136–7
 psychostimulants, for Lewy
 body dementia, 95
 quality of life (QoL), in Lewy
 body dementia, 98
 radioactivity, 93
 RAID. *See* Rating Anxiety in
 Dementia Scale
 RANZCP, 217, 223–4
 rare dementias, 49
 Rascovsky diagnostic criteria,
 102–3
 Rating Anxiety in Dementia
 Scale (RAID), 148
 rating instruments, 22
 RBD. *See* REM sleep behaviour
 disorder
 referrals, 232
 refugees, 281–2
 age cut-offs, 283–4
 defining, 282
 health inequalities, 284–6
 needs of, 286–7
 scale of problems with,
 282–3
 relatives, interviews with, 16
 relaxation training (RT), 149
 REM sleep behaviour disorder
 (RBD)
 Lewy body dementia, 91
 management of, 96
 reminiscence therapy (RT), 205
 with older people, 207–8
 renal failure, in OABD, 126–7
 repetitive Transcranial
 Magnetic Stimulation
 (rTMS), 199
 approval of, 199
 continuation of, 200
 for depression, 199
 efficacy of, 199–200
 safety of, 200
 resilience
 physical, 1
 psychological, 1
 retrograde memory, 32
 right temporal lobe atrophy
 (RTL), 103–4
 risk assessment, 15, 20–1
 anxiety disorders, 299
 general principles for, 20–1
 risk factors
 AD, 73–4
 alcohol consumption and,
 154
 for delirium, 57–8
 for disability, 2–3
 for morbidity, 3–4
 VaD, 81, 85
 risk formulation, 21
 risperidone, 61–2, 181–2
 rivastigmine
 pharmacokinetics of, 180
 tolerability of, 180
 Royal College of Psychiatrists,
 20–1
 RT. *See* relaxation training;
 reminiscence therapy
 RTL. *See* right temporal lobe
 atrophy
 rTMS. *See* repetitive
 Transcranial Magnetic
 Stimulation
 salience network, 35
 SATSA. *See* Swedish Adoption/
 Twin Study of Ageing
 Scheltens scale, 41–2
 schizophrenia, 6–7
 haloperidol in, 139
 late-onset, 135–40
 psychosis and, 135–6
 treatment, 135–40
 scholarship, 224–5
 seizure threshold (ST), 197–8
 selective serotonin reuptake
 inhibitors (SSRI), 118,
 183–4, 299–300
 for anxiety disorders, 148–9
 self-harm assessment, 20–1,
 300–1
 differential diagnosis, 301
 exam tips, 301
 management, 301
 self-medication, 161
 serotonin, 74–5
 serotonin norepinephrine
 reuptake inhibitors
 (SNRIs), 148–9
 setting, in psychiatry, 16–17
 sexual activity, lifestyle
 choices, 8
 simultanagnosia, 29
 SIVD. *See* subcortical ischaemic
 vascular dementia
 sleep
 dementia and, 265
 disturbances, 265
 lifestyle choices, 9
 small vessel disease (SVD), 46–7
 smoking, 3–4
 lifestyle choices, 9–10
 medical disorders, 160
 SNRIs. *See* serotonin
 norepinephrine reuptake
 inhibitors
 social activity
 in AD, 76
 lifestyle choices, 8
 social anxiety disorder, 146
 social cognition, 27
 assessment of, 35
 defining, 34–5
 psychological models, 34–5
 social history, in psychiatry,
 18–19

- SOD. *See* superoxide dismutase
 SPECT, 42–3
 speech, assessment, 19
 SSD. *See* Sub-Syndromal Depression
 SSRI. *See* selective serotonin reuptake inhibitors
 ST. *See* seizure threshold
 stroke, 28
 structural imaging, in Lewy body dementia, 92–3
 structural MRI, 42–3
 subcortical ischaemic vascular dementia (SIVD), diagnosis of, 80
 substance misuse
 anxiety disorders and, 154
 assessment, 155–7
 defining, 153
 drug interactions, 154–5
 epidemiology of, 153–4
 history of, 156
 identification of, 155
 insomnia and, 154
 integrated services for, 162
 pain and, 154
 psychiatric disorders and, 157
 psychological treatment, 160–2
 psychosis and, 136–7
 screening, 156–7
 treatment, 160
 subsyndromal delirium, 56
 Sub-Syndromal Depression (SSD), 112–13
 subthreshold anxiety, 147
 sugar, 9
 ageing theories and, 6
 suicide, MDD and, 119–20
 superoxide dismutase (SOD), 5
 suvorexant, 62
 SVD. *See* small vessel disease
 Swedish Adoption/Twin Study of Ageing (SATSA), 11
 symptom control, in palliative care, 242
 tacrine, 179
 TAME. *See* Treating Age with Metformin Study
 tau deposits, 46, 74
 tau hypothesis, AD, 74
 tau-PET, 46
 TCA. *See* tricyclic anti-depressants
 telemedicine, 232
 telomeres, 4–5
 testamentary capacity, 275–6
 thiamine deficiency, 33
 thought diaries, 208–10
 thyroid dysfunction, in OABD, 126
 tracers, in Lewy body dementia, 93
 Treating Age with Metformin Study (TAME), 6
 tricyclic anti-depressants (TCA), 148–9, 183–4
 UK Biobank, 51
 unilateral spatial neglect, 28
 VaD. *See* vascular dementia
 vascular cognitive disorder (VCD), 80–1
 vascular cognitive impairment (VCI), 80–1
 vascular dementia (VaD), 42, 46–8, 79
 AD and, 82
 brain imaging, 82–4
 changes in, 79
 CT for, 82–3
 genetics, 81–2
 Hachinski criteria in, 80
 interventions for, 85
 lesion location in, 82
 lifestyle choices and, 84
 medications for, 84, 178
 molecular imaging, 83
 pathology, 79–80
 prevention, 83–4
 risk factors, 81, 85
 subcortical ischaemic, 80
 treatment, 83–4
 types, 82
 Vascular Impairment in Cognition Classification Consensus Study (VICCCS), 81
 VCD. *See* vascular cognitive disorder
 VCI. *See* vascular cognitive impairment
 VICCCS. *See* Vascular Impairment in Cognition Classification Consensus Study
 vigilance, 28–9
 visual agnosias, 29
 visual information, 29–30
 vitamin C, 5
 vitamin D deficiency, 4–5
 vitamin E, 5
 vulnerability, 278–9
 Wales Mental Capacity Act, 262
 Walker, Matthew, 9
 WE. *See* Wernicke's Encephalopathy
 weight gain, 7
 in OABD, 126
 Werner Syndrome, 4
 Wernicke's Encephalopathy (WE), 159–63, 295
 white matter hyperintensities (WMH), 47, 79, 115
 appearance of, 47
 Whitehall-II Imaging sub-study, 51
 WHO. *See* World Health Organization
 Wisconsin Card Sorting Test, 34
 withdrawal
 alcohol, 160
 benzodiazepines, 158
 delirium tremens, 158
 WMH. *See* white matter hyperintensities
 working memory, 33–4
 World Health Organization (WHO), 123–4
 World Mental Health Survey Initiative, 124–5
 Worry Scale (WS), 148
 years lived with disability (YLD), 2